# OPA3

## Overview
The OPA3 gene encodes the outer mitochondrial membrane lipid metabolism regulator OPA3, a protein integral to mitochondrial dynamics and function. This protein is primarily localized in the mitochondrial outer membrane and is involved in processes such as mitochondrial fission and fragmentation, playing a crucial role in maintaining mitochondrial morphology and cellular health. OPA3 is categorized as a mitochondrial membrane protein and is known to interact with other proteins involved in mitochondrial dynamics, such as Mfn1, suggesting a regulatory role in balancing mitochondrial fission and fusion. Mutations in the OPA3 gene are associated with several hereditary conditions, including autosomal dominant optic atrophy and cataract (ADOAC) and Costeff syndrome, which are characterized by vision loss and neurological symptoms. These mutations often lead to increased cellular sensitivity to apoptotic stimuli, highlighting the gene's significance in neurodegenerative and systemic diseases (Reynier2004OPA3; Ryu2010Optic; Bourne2016Optic).

## Structure
The OPA3 gene encodes a protein consisting of 179 amino acids, with a predicted molecular weight of approximately 20 kDa (Anikster2001Type). The primary structure includes a mitochondrial targeting peptide, NRIKE, located at amino acid residues 25-29, suggesting its export to the mitochondrion (Anikster2001Type). The secondary structure of the OPA3 protein is composed of 61% alpha helix, 12% extended strand, 4% beta turn, and 22% random coil (Anikster2001Type). 

The protein contains a putative mitochondrial N-targeting signal sequence and a C-terminal coiled-coil domain, which may be involved in its localization to the inner mitochondrial membrane (Reynier2004OPA3). The OPA3 protein is suggested to be a single-pass membrane protein, potentially forming multimeric structures, such as dimers, under non-reducing conditions (Powell2011Mitochondrial). 

OPA3 is expressed as two splice variants, OPA3A and OPA3B, which share 47 N-terminal amino acids and are primarily targeted to mitochondria (Huizing2010OPA3). The C-terminal sequences of these variants contain peroxisomal sorting signals, although their mitochondrial localization is predominant (Huizing2010OPA3).

## Function
The OPA3 gene encodes a protein that is integral to the mitochondrial outer membrane and plays a significant role in mitochondrial dynamics, particularly in mitochondrial fission and fragmentation. In healthy human cells, OPA3 is crucial for maintaining mitochondrial morphology, which is essential for normal cellular function. The protein's activity is associated with increased cellular sensitivity to apoptotic stimuli, although it does not directly induce apoptosis. Instead, OPA3 overexpression sensitizes cells to apoptotic stimuli, indicating its role in potentiating cell death through mitochondrial fragmentation (Ryu2010Optic).

OPA3 is involved in mitochondrial fragmentation, a process that is independent of the DRP1/FIS1 pathway, known mediators of mitochondrial fission. This suggests that OPA3 functions as a mitochondrial fission factor or an inhibitor of fusion (Ryu2010Optic). The protein is localized in the mitochondrial outer membrane, with its N-terminal region exposed to the mitochondrial intermembrane space and its C-terminal region exposed to the cytosol, which is crucial for its role in mitochondrial dynamics and function (Ryu2010Optic).

Mutations in OPA3 are linked to optic neuropathies, such as Costeff optic atrophy syndrome, characterized by increased susceptibility to apoptotic stimuli and loss of retinal ganglion cells (Ryu2010Optic).

## Clinical Significance
Mutations in the OPA3 gene are linked to several hereditary conditions, primarily affecting vision and neurological function. One of the most notable conditions associated with OPA3 mutations is autosomal dominant optic atrophy and cataract (ADOAC), characterized by progressive vision loss and cataract formation. Specific mutations, such as G93S and Q105E, have been identified in affected families and are believed to increase susceptibility to apoptosis, contributing to the disease pathology (Reynier2004OPA3).

OPA3 mutations are also implicated in autosomal recessive 3-methylglutaconic aciduria type III, also known as Costeff syndrome. This condition is marked by optic atrophy, spasticity, and other neurological symptoms, particularly prevalent in individuals of Iraqi-Jewish descent (Bourne2016Optic). The OPA3 gene's role in mitochondrial dynamics suggests that its mutations can lead to disrupted mitochondrial morphology, increasing cellular sensitivity to apoptotic stimuli and contributing to the pathogenesis of optic atrophy (Ryu2010Optic).

In addition to visual impairments, OPA3 mutations have been associated with systemic conditions such as peripheral neuropathy, autonomic neuropathy, and metabolic dysfunctions, as seen in Costeff syndrome and other related disorders (Bourne2016Optic; Navein2016Disrupted). These findings underscore the clinical significance of OPA3 in maintaining mitochondrial integrity and its impact on neurodegenerative and systemic diseases.

## Interactions
OPA3 is involved in mitochondrial dynamics and interacts with several proteins, influencing mitochondrial morphology and function. It is located in the mitochondrial outer membrane and plays a role in mitochondrial fission. OPA3 can induce mitochondrial fragmentation independently of known fission mediators such as DRP1 and FIS1, suggesting it may act as a fission factor in a DRP1/FIS1-independent pathway (Ryu2010Optic). 

OPA3 also interacts with endogenous Mfn1, a protein involved in mitochondrial fusion, indicating a potential regulatory role in balancing mitochondrial fission and fusion processes (Ryu2010Optic). This interaction suggests that OPA3 may influence the dynamic equilibrium between mitochondrial fission and fusion, which is crucial for maintaining mitochondrial function and cellular health.

Mutations in OPA3, such as the G93S mutation, have been linked to increased susceptibility to apoptosis, which is associated with optic neuropathies like Costeff syndrome. These mutations may alter OPA3's interactions or its ability to regulate mitochondrial dynamics, contributing to disease pathogenesis (Ryu2010Optic). The study of OPA3's interactions and their implications for mitochondrial function continues to be an important area of research.


## References


[1. (Huizing2010OPA3) Marjan Huizing, Heidi Dorward, Lien Ly, Enriko Klootwijk, Robert Kleta, Flemming Skovby, Wuhong Pei, Benjamin Feldman, William A. Gahl, and Yair Anikster. Opa3, mutated in 3-methylglutaconic aciduria type iii, encodes two transcripts targeted primarily to mitochondria. Molecular Genetics and Metabolism, 100(2):149–154, June 2010. URL: http://dx.doi.org/10.1016/j.ymgme.2010.03.005, doi:10.1016/j.ymgme.2010.03.005. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2010.03.005)

[2. (Ryu2010Optic) Seung-Wook Ryu, Hyeon Joo Jeong, Myunghwan Choi, Mariusz Karbowski, and Chulhee Choi. Optic atrophy 3 as a protein of the mitochondrial outer membrane induces mitochondrial fragmentation. Cellular and Molecular Life Sciences, 67(16):2839–2850, April 2010. URL: http://dx.doi.org/10.1007/s00018-010-0365-z, doi:10.1007/s00018-010-0365-z. This article has 57 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-010-0365-z)

[3. (Navein2016Disrupted) Alice E. Navein, Esther J. Cooke, Jennifer R. Davies, Terence G. Smith, Lois H. M. Wells, Atsushi Ohazama, Christopher Healy, Paul T. Sharpe, Sam L. Evans, Bronwen A. J. Evans, Marcela Votruba, and Timothy Wells. Disrupted mitochondrial function in the opa3l122pmouse model for costeff syndrome impairs skeletal integrity. Human Molecular Genetics, pages ddw107, April 2016. URL: http://dx.doi.org/10.1093/hmg/ddw107, doi:10.1093/hmg/ddw107. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddw107)

[4. (Reynier2004OPA3) P Reynier. Opa3 gene mutations responsible for autosomal dominant optic atrophy and cataract. Journal of Medical Genetics, 41(9):e110–e110, September 2004. URL: http://dx.doi.org/10.1136/jmg.2003.016576, doi:10.1136/jmg.2003.016576. This article has 116 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.2003.016576)

[5. (Anikster2001Type) Yair Anikster, Robert Kleta, Avraham Shaag, William A. Gahl, and Orly Elpeleg. Type iii 3-methylglutaconic aciduria (optic atrophy plus syndrome, or costeff optic atrophy syndrome): identification of the opa3 gene and its founder mutation in iraqi jews. The American Journal of Human Genetics, 69(6):1218–1224, December 2001. URL: http://dx.doi.org/10.1086/324651, doi:10.1086/324651. This article has 137 citations.](https://doi.org/10.1086/324651)

[6. (Bourne2016Optic) Stephanie C. Bourne, Katelin N. Townsend, Casper Shyr, Allison Matthews, Scott A. Lear, Raj Attariwala, Anna Lehman, Wyeth W. Wasserman, Clara van Karnebeek, Graham Sinclair, Hilary Vallance, and William T. Gibson. Optic atrophy, cataracts, lipodystrophy/lipoatrophy, and peripheral neuropathy caused by a de novo opa3 mutation. Molecular Case Studies, 3(1):a001156, October 2016. URL: http://dx.doi.org/10.1101/mcs.a001156, doi:10.1101/mcs.a001156. This article has 10 citations.](https://doi.org/10.1101/mcs.a001156)

[7. (Powell2011Mitochondrial) Kate A. Powell, Jennifer R. Davies, Elaine Taylor, Michael A. Wride, and Marcela Votruba. Mitochondrial localization and ocular expression of mutant opa3 in a mouse model of 3-methylglutaconicaciduria type iii. Investigative Opthalmology &amp; Visual Science, 52(7):4369, June 2011. URL: http://dx.doi.org/10.1167/iovs.10-6406, doi:10.1167/iovs.10-6406. This article has 14 citations.](https://doi.org/10.1167/iovs.10-6406)